VELIA/GOG-3005试验中研究者与盲态独立中心评估的高级别浆液性卵巢癌无进展生存期分析
该研究基于3期VELIA/GOG-3005试验,比较veliparib联合卡铂-紫杉醇并维持治疗与单纯化疗在新诊断卵巢癌中的无进展生存期(PFS),主要分析采用研究者评估,补充分析采用盲态独立中心审查(BICR)。结果显示两组风险比一致,研究者评估与BICR总体一致率在78%和75%,支持研究者评估PFS的可靠性。
要点
- 在ITT人群中,研究者评估的中位PFS为23.5个月对17.3个月(HR 0.683,95%CI 0.562-0.831;P<0.001)。
- BICR评估的中位PFS为29.3个月对19.2个月(HR 0.687,95%CI 0.504-0.806)。
- 研究者评估与BICR的总体一致率在veliparib全程组和对照组分别为78%和75%。
核心结论
- BICR和研究者评估的PFS风险比一致,未提示研究者偏倚,支持卵巢癌试验中研究者评估PFS的可靠性。
研究设计与样本
- 3期VELIA/GOG-3005试验的事后分析,患者接受veliparib或安慰剂联合卡铂-紫杉醇6周期并维持治疗30周期。
主要发现
- 在ITT人群中,研究者评估的中位PFS为23.5个月对17.3个月(HR 0.683,95%CI 0.562-0.831;P<0.001)。
- 在ITT人群中,BICR评估的中位PFS为29.3个月对19.2个月(HR 0.687,95%CI 0.504-0.806)。
- 在ITT人群中,研究者评估与BICR的总体一致率在veliparib全程组和对照组分别为78%和75%。
关键数值与推荐
- 主要分析比较veliparib全程组与单纯卡铂-紫杉醇组在BRCA突变、HRD和ITT人群中的PFS。
- 探索性分析包括BRCA野生型、HRP和HRD+BRCA野生型人群的PFS。
临床怎么用
- 在卵巢癌临床试验中,研究者评估的PFS可作为可靠终点,与BICR结果一致性良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the phase 3 VELIA/GOG-3005 trial, veliparib added to carboplatin-paclitaxel and continued as maintenance improved progression-free survival (PFS) compared to carboplatin-paclitaxel alone in patients with newly diagnosed ovarian carcinoma. Primary analysis of PFS was by investigator (INV) assessment, with a supplemental analysis of PFS by blinded independent central review (BICR). METHODS: Patients received veliparib or placebo with carboplatin-paclitaxel (6 cycles) and as maintenance (30 additional cycles). The primary analysis compared PFS in the veliparib-throughout arm to the carboplatin-paclitaxel only arm in the BRCA mutation (BRCAm), homologous recombination deficiency (HRD), and intention-to-treat (ITT) populations. Exploratory analyses of PFS in BRCA wildtype (BRCAwt), homologous recombination proficient (HRP), and HRD + BRCAwt populations were also performed. PFS per BICR and overall concordance rates between INV and BICR assessments were analyzed. RESULTS: Hazard ratios for PFS by INV and BICR were consistent in each of the primary analysis and exploratory populations. In the ITT population, median PFS per INV was 23.5 months in the veliparib-throughout arm versus 17.3 months in the control arm (hazard ratio [HR] 0.683, 95% confidence interval [CI] 0.562-0.831; P < 0.001). Median PFS by BICR was 29.3 months versus 19.2 months (HR 0.687, 95% CI 0.504-0.806). In the ITT population, the overall concordance rates between INV and BICR were 78% and 75% for the veliparib-throughout and control arms, respectively. CONCLUSIONS: Hazard ratios for PFS per BICR and per INV were consistent, with no suggestion of investigator bias. These findings support the reliability of PFS by INV in ovarian cancer trials.
引用
- Aghajanian C, Bookman MA, Fleming GF, et al. Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. Gynecol Oncol. 2021. PMID: 34112513. doi:10.1016/j.ygyno.2021.05.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。